Exelixis narrows 2025 revenue guidance to $2.3B–$2.35B amid accelerated GI franchise expansion and new pivotal trials (NASDAQ:EXEL)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...